Faculty Information   
   日本語 >>
  1. TOP page
    2. >
  2. Institute for Advanced Medical Sciences
    3. >
  3. Laboratory of Medical Innovation

Journal
Presentation
    （Last updated : 2022-03-18 11:19:37）
  Kubo Shiyuuji
   Department   Laboratory/Facility  , Institute for Advanced Medical Sciences
   Position  
■ Journal
1. Original article　 Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis. 2013/07
2. Original article　 FK506 induces endothelial dysfunction through attenuation of Akt and ERK1/2 independently of calcineurin inhibition and the caspase pathway. 2013/09
3. Original article　 Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. 2013/11
4. Original article　 Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus. 2013/12
5. Original article　 Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. 2014/02
6. Original article　 Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. 2015/03
7. Original article　 Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells. 2015/06
8. Original article　 Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells. 2015/06
9. Original article　 Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model. 2015/08
10. Original article　 Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams. 2016/01
11. Original article　 Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. 2016/12 Link
12. Original article　 A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma 2020/05
13. Original article　 Assessment of circulating microRNA specific for patients with familial adenomatous polyposis 2021/05
Display 5 items
Display all(13)
■ Presentation
1. Hybrid vectors as trojan horses; adventure with adenovirus for successful gene therapy.  2013/04/15
2. Anti-Tumor effects of ad-p53 on INK4A/ARF-defective mesothelioma are influenced positively by small G protein inhibitors but negative by heat shock protein 90 inhibitors  2013/05/16
3. Comparative evaluation of the antitumor activity of anti-anqioqeni proteins delivered by lentivirus vector in humaan maliqnant mesothelioma model  2013/05/16
4. Development of dual targeted oncolytic adenovirus for human malignant mesothelioma  2013/05/18
5. Adventure with viruses toward the success of gene therapy against malignant mesothelioma  2013/06/04
6. Bisphosphonates and Nutlin-3a augments cytotoxicity induced by adenovirally expressed p53 in p53 wild-type mesothelioma  2013/07/05
7. Midkine promoter-driven oncolytic adenovirus with adenovirus 35 fiber modification achieves enhanced transduction of human osteosarcoma cells  2013/07/06
8. Biological roles of deletion of PBRM1 and BAP1 in malignant mesotheliomas  2013/10/03
9. Bisphosphonates produce cytotoxic effects on mesothelioma through inhibiting topoisomerase II and rab functions  2013/10/04
10. Dual targeted adenovirus for oncolytic virotherapy in experimental human osteosarcoma  2013/10/05
11. SF3B1 inhibitor as a novel molecular targeted drug candidate for colorectal cancer  2013/10/05
12. SF3B1 inhibitor as a novel molecular targeted drug candidate for colorectal cancer  2013/10/05
13. Prodrug activator gene therapy using replicating gibbon ape leukemia virus in an experimental model of human malignant mesothelioma  2014/08/06
14. Combination of nutlin-3a and Hsp90 inhibitors produces p53-dependent synergism on human mesothelioma cells  2014/09/25
15. Alternative splicing of c-myc transcriptional repressor, FIR,contributes T-ALL by c-Myc activation  2014/09/26
16. FIR splicing as a molecular sensor for bleomycin-induced DNA damage response pathway  2014/09/26
17. Rare germline variants of transcription regulator genes in malignant mesothelioma  2014/09/27
18. SF3B1 is a novel molecular target for induction of synthetic lethality with the other anticancer drug.  2014/09/27 Link
19. Suicide gene therapy by replicating gibbon ape leukemia virus in an experimental model of human malignant mesothelioma  2014/09/27
20. Transduced p53 enhances cytotoxic effects achieved with oncolytic adenoviruses on pancreatic carcinoma cells  2014/09/27
21. Comparative evaluation of suicide gene therapy using retroviral peplicating vectors in an experimental model of human malignant mesothelioma  2014/10/21
22. Enhanced transduction and antitumor efficiency of fiber-modified,midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma  2014/10/21
23. Educational program on human genetics and clinical genetics for medical students  2014/11/22
24. Brain Vascular Pericytes Acquire Stemness Following Ischemic Insult  2015/04/17
25. Brain pericytes following ischemia acquire neural phenotypes in a mesenchymal-epithelial transition like manner  2015/07/30
26. The CiTi Japan Program introduced into undergraduate medical education  2016/04/04
27. Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model  2016/05/04
28. Customization of virotherapy with replicating retroviral replicating vectors on the basis of cellular receptor expression profiles.  2016/07
29. Customization of virotherapy with retroviral replicating vectors on the basis of cellular receptor expression profiles.  2016/10
30. A MDMX inhibitor produces cytotoxicity in a p53-independentmanner but achieves synergistic action with MDM2 inhibitors  2016/10/07
31. Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors in an Experimental Model of Human Osteosarcoma  2017/05/10
32. An Inhibitor for the MDM2-p53 Interaction Produces Synergistic Cytotoxicity with Oncolytic Adenoviruses on Mesothelioma with Wild-Type p53 Genotype  2017/05/12
33. A MDM2 inhibitor augments cytotoxicity of oncolytic adenoviruses defective of E1B 55kDa molecules through enhancing DNA damages and apoptosis in mesothelioma  2017/07/20
34. Retroviral replicating vector-mediated prodrug activator gene therapy for osteosarcoma  2017/07/21
35. A Weel kinase inhibitor increases apoptosis of replication-competent adenoviruses through induction of mitotic catastrophe and enhancement of viral replications  2017/07/22
36. A MDM2 inhibitor achieves synergistic cytotoxicity with oncolytic adenoviruses on mesothelioma with the wild-type p53  2017/09/30
37. Retroviral replicating vector-mediated suicide gene therapy for osteosarcoma.  2017/09/30 Link
38. Peritoneal dissemination of rectal cancer cells from patient-derived.  2019/09/26 Link
39. FOXQ1 expression is associated and K-RAS/BRAF mutation status in colorectal cancer.  2019/09/28 Link
Display 5 items
Display all(39)
mail